Publications by authors named "C Orts Arqueros"
Approximately one-third of patients with breast cancer have comorbidities at the time of their diagnosis. Recommendations for managing metastatic breast cancer are usually based on the results of clinical trials, which often limit patients with comorbidities. However, comorbidities greatly influence the quality of life, patient survival rate and treatment choice, particularly in older patients.
View Article and Find Full Text PDFArticle Synopsis
- Deregulation of small non-coding RNAs (sncRNAs) is linked to metastasis in early-stage breast cancer, with RNA sequencing performed on samples from 60 patients.
- Analysis revealed that most sncRNAs were classified as small nucleolar RNA (snoRNA) and small nuclear RNA (snRNA), with no significant expression differences between tumor and sentinel lymph node samples.
- A specific signature of six snoRNAs was identified as potential markers for locoregional metastasis and patient outcomes, highlighting the need for further research to validate these findings in larger patient groups.
Currently, therapy response cannot be accurately predicted in HER2-negative breast cancer (BC). Measuring stromal tumour-infiltrating lymphocytes (sTILs) and mediators of the tumour microenvironment and characterizing tumour-infiltrating immune cells (TIICs) may improve treatment response in the neoadjuvant setting. Tumour tissue and peripheral blood samples were retrospectively collected from 118 patients, and sTILs were evaluated.
View Article and Find Full Text PDFSecreted protein acidic and rich in cysteine (SPARC) expression has been proposed as a prognostic and predictive biomarker for some cancer types, but knowledge about the predictive value of polymorphisms in the context of neoadjuvant therapy for breast cancer (BC) is lacking. In 132 HER2-negative BC patients treated with neoadjuvant chemotherapy, we determined polymorphisms in the gene and analyzed their association with outcome. We also determined SPARC protein expression in tumor tissue.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the connection between tumor-derived microRNAs (miRNAs) and their presence in the plasma of early breast cancer patients, focusing on whether these miRNAs can serve as noninvasive biomarkers for disease diagnosis.
- Analysis revealed that circulating miRNAs are generally downregulated compared to those found in tumor tissue and sentinel lymph nodes, but specific miRNAs like miR-643a-3p and miR-223 were upregulated in patients with positive lymph nodes.
- The findings indicate that certain circulating miRNAs could potentially serve as indicators of lymph node metastases in early breast cancer, but further research is needed to confirm these results and explore the biological roles of these miRNAs.